Results 211 to 220 of about 398,911 (393)

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review. [PDF]

Pharmaceuticals (Basel)
Bieś R, Krzystanek M, Górski M, Koźmin-Burzyńska A, Warchala A, Trędzbor B, Martyniak E, Fojcik J.   +7 more
europepmc   +1 more source

Molecular imprinting for neurology: Materials, applications, and limitations

Ibrain, EarlyView.
Molecularly imprinted materials: diagnostic, therapeutic and research applications in neurology. Molecularly imprinted materials offer high specificity and affinity for target molecules in neurological applications. This review highlights their synthesis, characterisation, and use in diagnostics, research and therapeutics.
Xiaohan Ma, Yingqi Ma, Claudia Marino, Alessandro Poma   +3 more
wiley   +1 more source

From pathogenesis to treatment: the emerging role of ferroptosis in Parkinson's disease. [PDF]

Front Immunol
Tu R, Han Z, Zhang H, Jia X, Sun T, Liu H, Li J, Tang M, Wang S.   +8 more
europepmc   +1 more source

Neuroprotective Effects of β-Caryophyllene against Dopaminergic Neuron Injury in a Murine Model of Parkinson’s Disease Induced by MPTP [PDF]

, 2017
Juan Manuel Viveros–Paredes, Rocío E. González-Castañeda, Jürg Gertsch, V. Chaparro‐Huerta, Rocío Ivette López-Roa, Eduardo Vázquez-Valls, Carlos Beas‐Zárate, Antoni Camins, Mario Eduardo Flores-Soto   +8 more
openalex   +1 more source

Weizmannia coagulans XY2 Mitigates Copper Neurotoxicity via Gut–Brain Axis Modulation of Tryptophan Metabolism and Oxidative‐Inflammatory Crosstalk

iMetaOmics, EarlyView.
Copper interferes with tryptophan metabolism and 5‐HT levels by modulating intestinal flora. Intestinal barrier breakdown and inflammatory response trigger nerve damage under copper exposure. W. coagulans XY2 alleviates copper‐induced neurotoxicity by targeting a multi‐dimensional “tryptophan metabolism‐antioxidant defense‐gut‐brain axis” network.
Yufang Gao, Xiaodong Zheng, Fujie Yan
wiley   +1 more source

Synergy between stem cell therapy and brain-derived neurotrophic factor (BDNF) in Parkinson's disease: a mini-review of combined neuroregenerative strategies. [PDF]

Chin Neurosurg J
Jonny J, Larasati AD, Sunjaya QA, Faried A.   +3 more
europepmc   +1 more source

White Matter Dysfunction and Neurotransmitter Basis Underlying the Freezing of Gait in Parkinson's Disease

iNew Medicine, EarlyView.
In the freezing of gait in Parkinson's disease, white matter shows decreased local activity but increased functional connectivity. These distinct dysfunctions are uniquely associated with specific neurotransmitter systems (GABA, dopamine, etc.), mapping a new neurochemical basis for this debilitating symptom. ABSTRACT Freezing of gait (FOG) is a severe
Pingping Liu, Jinmei Sun, Lili Hu, Xin Chen, Jinying Han, Liuzhenxiong Yu, Siyu Fan, Rong Ye, Kai Wang, Gong‐Jun Ji, Panpan Hu   +10 more
wiley   +1 more source

One-Carbon Metabolism and Midbrain Dopaminergic Cells in Lesch-Nyhan Disease. [PDF]

Mol Syndromol
Alsuwaidi S, Ernst C.
europepmc   +1 more source

In vivo pharmacology of the dopaminergic stabilizer pridopidine

, 2010
Henrik Pontén, Johan Kullingsjö, Sören Lagerkvist, Peter Martin, Fredrik Pettersson, Clas Sonesson, Nicholas Waters, Nicholas Waters   +7 more
openalex   +1 more source

LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease

Proceedings of the National Academy of Sciences of the United States of America, 2018
M. Nguyen, D. Krainc
semanticscholar   +1 more source